Broadening Eligibility Criteria to Make Clinical Trials More Representative: American Society of Clinical Oncology and Friends of Cancer Research Joint Research Statement
Top Cited Papers
- 20 November 2017
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 35 (33), 3737-3744
- https://doi.org/10.1200/jco.2017.73.7916
Abstract
Purpose The primary purposes of eligibility criteria are to protect the safety of trial participants and define the trial population. Excessive or overly restrictive eligibility criteria can slow trial accrual, jeopardize the generalizability of results, and limit understanding of the intervention’s benefit-risk profile. Methods ASCO, Friends of Cancer Research, and the US Food and Drug Administration examined specific eligibility criteria (ie, brain metastases, minimum age, HIV infection, and organ dysfunction and prior and concurrent malignancies) to determine whether to modify definitions to extend trials to a broader population. Working groups developed consensus recommendations based on review of evidence, consideration of the patient population, and consultation with the research community. Results Patients with treated or clinically stable brain metastases should be routinely included in trials and only excluded if there is compelling rationale. In initial dose-finding trials, pediatric-specific cohorts should be included based on strong scientific rationale for benefit. Later phase trials in diseases that span adult and pediatric populations should include patients older than age 12 years. HIV-infected patients who are healthy and have low risk of AIDS-related outcomes should be included absent specific rationale for exclusion. Renal function criteria should enable liberal creatinine clearance, unless the investigational agent involves renal excretion. Patients with prior or concurrent malignancies should be included, especially when the risk of the malignancy interfering with either safety or efficacy endpoints is very low. Conclusion To maximize generalizability of results, trial enrollment criteria should strive for inclusiveness. Rationale for excluding patients should be clearly articulated and reflect expected toxicities associated with the therapy under investigation.Keywords
This publication has 22 references indexed in Scilit:
- Impact of Prior Cancer on Eligibility for Lung Cancer Clinical TrialsJNCI Journal of the National Cancer Institute, 2014
- Designing Therapeutic Clinical Trials for Older and Frail Adults With Cancer: U13 Conference RecommendationsJournal of Clinical Oncology, 2014
- Targeted Therapies in Brain MetastasesCurrent Treatment Options in Neurology, 2013
- Closing the Gap: Increases in Life Expectancy among Treated HIV-Positive Individuals in the United States and CanadaPLOS ONE, 2013
- Adolescent Dosing and Labeling Since the Food and Drug Administration Amendments Act of 2007JAMA Pediatrics, 2013
- Electrocardiograms (ECGs) in phase I anticancer drug development: the MD Anderson Cancer Center experience with 8518 ECGsAnnals of Oncology, 2012
- The American Society of Clinical Oncology's Blueprint for Transforming Clinical and Translational Cancer ResearchJournal of Clinical Oncology, 2012
- All-cause mortality in treated HIV-infected adults with CD4 >=500/mm3 compared with the general population: evidence from a large European observational cohort collaborationInternational Journal of Epidemiology, 2011
- Systematic Review of Barriers to the Recruitment of Older Patients With Cancer Onto Clinical TrialsJournal of Clinical Oncology, 2005
- A Study in Contrasts: Eligibility Criteria in a Twenty-Year Sample of NSABP and POG Clinical TrialsJournal of Clinical Epidemiology, 1998